特集 分子を撃つ　神経疾患治療の新しい水平線 CD52:アレムツズマブ

DOI Web Site PubMed
  • 森 雅裕
    千葉大学大学院医学研究院神経内科学

書誌事項

タイトル別名
  • Alemtuzumab, a Monoclonal Antibody against CD52: Hopes and Fears
  • CD52 : アレムツズマブ

この論文をさがす

説明

CD52, an antigen expressed on immune cells including mature T lymphocytes, is thought to be involved in immunomodulatory mechanisms. Alemtuzumab is a humanized monoclonal antibody against CD52, which causes a marked and long-term decrease in immune cells, especially CD4-positive T lymphocytes. A few randomized clinical trials have revealed the efficacy of alemtuzumab to be much greater than that of interferon-β in patients with relapsing-remitting multiple sclerosis. However, the development of other autoimmune disorders, including autoimmune thyroid disorders and thrombocytic purpura, because of alemtuzumab application has been considered an obstacle in its widespread use.

収録刊行物

  • BRAIN and NERVE

    BRAIN and NERVE 66 (10), 1179-1189, 2014-10-01

    株式会社医学書院

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ